Efficacy and Tolerance of Interferon ÃÂ² Plus Ribavirin Treatment for Chronic Hepatitis C Patients with Depression or Thrombocytopenia Comparison with Pegylated Interferon ÃÂ± Plus Ribavirin Treatment
|Hiroaki Ikezaki, Norihiro Furusyo*, Eiichi Ogawa, Motohiro Shimizu, Satoshi Hiramine, Kazuya Ura, Fujiko Mitsumoto, Kouji Takayama, Kazuhiro Toyoda, Masayuki Murata and Jun Hayashi|
|Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan|
|Corresponding Author :||Norihiro Furusyo
Department of General Internal Medicine
Kyushu University Hospital, 3-1-1 Maidashi
Higashi-ku, Fukuoka, 812-8582, Japan
E-mail: [email protected]
|Received April 03, 2014; Accepted April 22, 2014; Published May 05, 2014|
|Citation: Ikezaki H, Furusyo N, Ogawa E, Shimizu M, Hiramine S, et al. (2014) Efficacy and Tolerance of Interferon β Plus Ribavirin Treatment for Chronic Hepatitis C Patients with Depression or Thrombocytopenia Comparison with Pegylated Interferon α Plus Ribavirin Treatment. J Liver 3:155. doi: 10.4172/2167-0889.1000155|
|Copyright: © 2014 Ikezaki H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Objective: Limited data has been reported comparing natural human interferon β (nIFNβ) and pegylated IFN-α (PEG-IFNα) when Ribavirin (RBV) is combined. This case-control study was done to compare the efficacy and adverse effects of a combination treatment of nIFNβ or PEG-IFNα plus RBV for chronic hepatitis C patients.
Methods: Sixty patients with chronic hepatitis C, 42 infected with hepatitis C virus (HCV) genotype 1 and 18 infected with genotype 2, were treated with nIFNβ plus RBV. Of them, 23 (38.3%) suffered pre-treatment severe depression. Their data was compared with 60 undepressed patients treated with a combination of PEG-IFNα plus RBV. nIFNβ was given intravenously and PEG-IFNα was injected subcutaneously.
Results: Sustained virological response (undetectable HCV RNA at 24 weeks after the end of treatment) did not significantly differ between the nIFNβ and PEG-IFNα treated patients (genotype 1, 21.4% vs. 33.3%, P=0.328; genotype 2, 72.2% vs. 88.9%, respectively, P=0.402). None of the nIFNβ treated patients showed exacerbation of depression, while 7 (11.7%) of 60 PEG-IFNα treated patients developed severe depression or malaise. The platelet count of nIFNβ treated patients increased to higher than baseline after week 8, but the platelet count of PEG-IFNα treated patients decreased throughout the treatment. There were significant differences of the changes of platelet counts between the both groups throughout the treatment (all P<0.001).
Conclusion: nIFNβ plus RBV treatment was well tolerated by chronic hepatitis C patients with depression or thrombpcytopenia.